BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 33307035)

  • 1. PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF-κB Activity.
    Szydłowski M; Dębek S; Prochorec-Sobieszek M; Szołkowska M; Tomirotti AM; Juszczyński P; Szumera-Ciećkiewicz A
    Am J Pathol; 2021 Mar; 191(3):567-574. PubMed ID: 33307035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
    Szydłowski M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Derezińska E; Hoser G; Wasilewska D; Szymańska-Giemza O; Jabłońska E; Białopiotrowicz E; Sewastianik T; Polak A; Czardybon W; Gałęzowski M; Windak R; Zaucha JM; Warzocha K; Brzózka K; Juszczyński P
    Blood; 2017 Sep; 130(12):1418-1429. PubMed ID: 28698206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.
    Peters TL; Li L; Tula-Sanchez AA; Pongtornpipat P; Schatz JH
    Oncotarget; 2016 Sep; 7(39):63362-63373. PubMed ID: 27556513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.
    Guiter C; Dusanter-Fourt I; Copie-Bergman C; Boulland ML; Le Gouvello S; Gaulard P; Leroy K; Castellano F
    Blood; 2004 Jul; 104(2):543-9. PubMed ID: 15044251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of DLBCL with a PMBL gene expression signature.
    Duns G; Viganò E; Ennishi D; Sarkozy C; Hung SS; Chavez E; Takata K; Rushton C; Jiang A; Ben-Neriah S; Woolcock BW; Slack GW; Hsi ED; Craig JW; Hilton LK; Shah SP; Farinha P; Mottok A; Gascoyne RD; Morin RD; Savage KJ; Scott DW; Steidl C
    Blood; 2021 Jul; 138(2):136-148. PubMed ID: 33684939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.
    Chapuy B; Stewart C; Dunford AJ; Kim J; Wienand K; Kamburov A; Griffin GK; Chen PH; Lako A; Redd RA; Cote CM; Ducar MD; Thorner AR; Rodig SJ; Getz G; Shipp MA
    Blood; 2019 Dec; 134(26):2369-2382. PubMed ID: 31697821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
    Aladily TN; Mansour A; Alsughayer A; Sughayer M; Medeiros LJ
    Ann Diagn Pathol; 2019 Jun; 40():72-76. PubMed ID: 31075666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
    Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
    Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.
    Mottok A; Hung SS; Chavez EA; Woolcock B; Telenius A; Chong LC; Meissner B; Nakamura H; Rushton C; Viganò E; Sarkozy C; Gascoyne RD; Connors JM; Ben-Neriah S; Mungall A; Marra MA; Siebert R; Scott DW; Savage KJ; Steidl C
    Blood; 2019 Sep; 134(10):802-813. PubMed ID: 31292115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
    Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
    Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.
    Sakakibara A; Kohno K; Iwakoshi A; Moritani S; Fujishiro A; Kito K; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
    Pathol Int; 2020 Feb; 70(2):116-122. PubMed ID: 31894883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.
    Pelland K; Mathews S; Kamath A; Cohen P; Hudnall SD; Cotta CV; Xu ML
    Appl Immunohistochem Mol Morphol; 2018; 26(10):e101-e106. PubMed ID: 29189264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
    Ritz O; Guiter C; Castellano F; Dorsch K; Melzner J; Jais JP; Dubois G; Gaulard P; Möller P; Leroy K
    Blood; 2009 Aug; 114(6):1236-42. PubMed ID: 19423726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
    Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
    Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
    La Starza R; Messina M; Gianfelici V; Pierini V; Matteucci C; Pierini T; Limongi MZ; Vitale A; Roti G; Chiaretti S; Foà R; Mecucci C
    Leukemia; 2018 Aug; 32(8):1807-1810. PubMed ID: 29479063
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.
    Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC;
    Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation
    Burkhard R; Keller I; Arambasic M; Juskevicius D; Tzankov A; Lundberg P; Bruggmann R; Dirnhofer S; Radpour R; Novak U
    Haematologica; 2019 Apr; 104(4):766-777. PubMed ID: 30381301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.